PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 81: Articles 40001-40500 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Immunochemical quantitation of human transferrin in pregnancy and during administration of oral contraceptives.
  2. The impact of contraception on medical and surgical practice.
  3. Implantation of estradiol pellets for contraception. [L'implantation de pellets d'oestradiol dans la contraception.]
  4. Implications of contraception. A. metabolic effects of oral contraceptives.
  5. Incidence of side effects with contraceptive placebo.
  6. India's population/family planning program.
  7. India. Teaching of population dynamics and family planning in the curriculum of undergraduate medical education.
  8. India: mass communication in the family planning programme.
  9. Infarction of the small intestine associated with oral contraceptives.
  10. Influence of an oral contraceptive progestin-estrogen combination on simian uterine phosphatases.
  11. The influence of combined oral contraceptives on scalp hair growth. [Die Wirkung monophasischer Ovulationshemmer auf das Wachstum der Kopfhaare.]
  12. Influence of contraceptive gestogen pills on sexual behaviour and the spread of gonorrhoea.
  13. Influence of oral contraceptives on the presence and persistence of Candida albicans and beta-haemolytic streptococci in the vagina.
  14. The influence of oral contraceptives with and without an ovulation suppressant action on thyroid function tests: preliminary observations on differences in insulin response to glucose.
  15. 17-alpha-hydroxy, 19 norprogesterone capronate as a prolonged-action injectable contraceptive agent. [El capronato de 17 alfa-hidroxi, 19 nor-progesterona como agente anticonceptivo inyectable de deposito.]
  16. 4 cases of hyperplastic gingivitis during combined estrogen-progestagen contraception. [A propos de quatre cas de gingivite hyperplasique au decours de contraception par oestroprogestatif.]
  17. 9. Family planning in the framework of a national development plan.
  18. Aberrant glandular polypi of the uterine cervix associated with contraceptive pills; pathology and pathogenesis.
  19. Acceleration of a public health department family planning program: referral from well baby clinics in Muscogee County, Georgia.
  20. The acceptability and effectiveness of chlormadinone acetate 0.5 mg as an oral contraceptive.
  21. Acquired subclinical diabetes mellitus in women receiving oral contraceptive agents.
  22. Activities of the International Planned Parenthood Federation (I.P.P.F.)
  23. Acute exogenous reaction types during oral contraception. [Zur Frage akuter exogener Reaktionstypen unter Ovulationshemmern.]
  24. The administration of the family planning programme in Pakistan with special reference to the employment of paramedical personnel.
  25. Adopting family planning practice/methods- role of motivation, communication and education.
  26. Adoption of a new contraceptive in urban India.
  27. Adrenocortical function studies during oral contraception with chlormadinone acetate.
  28. Adrenocortical insufficiency related to oral contraceptives.
  29. Advances in contraception.
  30. Adverse cutaneous reaction to oral contraceptives.
  31. Adverse effects of oral contraceptives. [Danni da contracettivi orali.]
  32. AID's family planning strategy.
  33. Albumin metabolism and oral contraception.
  34. Alkaline phosphatase activity of polymorphonuclear leukocytes in relation to oral contraceptives.
  35. Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration, and substrate.
  36. Amenorrhea and galactorrhea following oral contraceptive therapy.
  37. Amenorrhea following oral contraceptives.
  38. Analysis of fertility and family planning patterns.
  39. Andrological changes in workers in the production of oral contraceptives. [Andrologische Veranderungen bei Beschaftigten der Produktion oraler Kontrazeptiva.]
  40. Anovular corpus luteum in a woman taking an oral contraceptive.
  41. Appendix 3. List of contraceptive products available in England and the United States.
  42. Appendix X-2: use-effectiveness of intrauterine contraception as a problem in competing risks.
  43. Are there general principles of contraceptive technology?
  44. Argentina. (Family planning)
  45. Assessment of psychological concomitants of oral contraceptives.
  46. Atypical asymptomatic uterine perforation by a metallic intrauterine contraceptive device. [Atipicna asimptomatska perforacija maternice metalnim intrauterinim kontraceptivnim uloskom.]
  47. Awareness and acceptance of different family planning in a rural population.
  48. Axillary vein thrombosis and pulmonary embolism possibly due to oral contraception.
  49. Background of family planning in a rural southern state.
  50. Bacteriological studies on the long term users of the intrauterine contraceptive device. (Abstract only)
  51. Bahamas (Family planning)
  52. Behavioral effects of contraception.
  53. Behavioral effects of gonadal hormones and contraceptive steroids in primates.
  54. Beliefs and attitudes about contraception among the poor.
  55. Beyond family planning.
  56. Bilateral carotid artery occlusion in a young adult: clinicopathological report of a case associated with oral contraceptives.
  57. Binovular twins in a patient taking oral contraceptives.
  58. Binovular twins in a patient taking oral contraceptives.
  59. Biochemical changes and implications following long-term use of oral contraception.
  60. Biochemical changes in uterus in the presence of intra-uterine contraceptive devices.
  61. Biochemistry of the human endometrium in users of the intrauterine contraceptive device.
  62. The biological effects of family planning: A. Preventive pediatrics: the potential of family planning.
  63. Biological mechanisms in conception and contraception.
  64. The biology of steroidal contraceptives.
  65. Birth control experience in Taiwan.
  66. Birth control knowledge and attitudes among unmarried pregnant adolescents: a preliminary report.
  67. Birth control methods - general considerations.
  68. The birth control pill and its ophthalmologic side effects.
  69. Birth control practice in Britain.
  70. Birth control, teenagers and the law.
  71. Birth control.
  72. Birth control. [Regulation des naissances.]
  73. Blood coagulation and oral contraception.
  74. The blood picture in contraception.
  75. Breast cancer manifest during contraceptive steroid therapy of two women with prior lactation mastitis.
  76. Building a national family planning program.
  77. Cancer and contraceptive devices.
  78. Carbohydrate metabolism and long-term use of oral contraceptives.
  79. Cardiovascular dynamics in women receiving oral contraceptive therapy.
  80. The case against the contraceptive pill.
  81. Case of Takayasu's syndrome accelerated (initiated?) by oral contraceptives.
  82. A Catholic pediatrician on family planning.
  83. Cerebral thrombosis and oral contraceptives.
  84. Cerebrovascular diseases associated with the use of oral contraceptives: a review of the literature.
  85. Ceylon family planning program: feedback reports, January-June 1969.
  86. Changes in blood coagulation and fibrinolysis in women receiving oral contraceptives.
  87. Changes in various indexes of maternal health observed after a program of family planning. [Cambios en algunos indices de salud materna observados despues de un programa de planificacion familiar.]
  88. Changing oral contraceptives.
  89. Characteristics and performance of family planning organizers in West Pakistan.
  90. Characteristics of contraceptors at a large hospital-based family planning program.
  91. Chemical contraceptives.
  92. The chemistry of steroidal contraceptives.
  93. A Chinese view of family planning in the developing world.
  94. Chlormadinone acetate 0.5 mg: a report on its effectiveness in continuous daily use as an oral contraceptive.
  95. Chlormadinone acetate as oral contraceptive.
  96. Chlormadinone acetate as oral contraceptive.
  97. Chlormadinone acetate as oral contraceptive: a clinical trial.
  98. Chlormadinone acetate continuous in contraception - the early days and recent experience.
  99. Choice of oral contraceptive.
  100. Choice of oral contraceptives.
  101. Chromosomes and an oral contraceptive (Lyndiol 2.5)
  102. The clients of family planning centers. [Les consultants des centres de planning familial.]
  103. Clinical and pathological evaluation of SH 850 for contraception.
  104. Clinical aspects of intrauterine contraception and pregnancy. [Graviditet trots intrauterint preventivmedel.]
  105. Clinical aspects of the effects of oral contraceptives on the veins. [Zur Klinik der Venenwirkung oraler Kontrazeptiva.]
  106. Clinical course and laboratory data in hypertension associated with oral contraceptives.
  107. Clinical evaluation of a plastic ring intra-uterine contraceptive device (INCON)
  108. A clinical evaluation of long-term continuous use of norethynodrel-mestranol for contraception.
  109. Clinical experience with oral contraceptives in Japan. (Abstract only)
  110. Clinical experiences with Depo-provera: an injectable contraceptive. 1969.
  111. Clinical observations of vision abnormalities of patients taking oral contraceptives.
  112. Clinical study of an oral contraceptive (Lyndiol 2.5 mg.) in Korean women. (Abstract only)
  113. Clinical trial with oral contraceptives.
  114. Clotting factors and oral contraception: design of trials and results with chlormadinone acetate.
  115. Communication in family planning: twilight zone between acceptance and motivation.
  116. Communications in rural family planning.
  117. A comparative study for delinquents and nondelinquents at Nanakuli family planning clinic in Hawaii U.S.A.
  118. Comparative study of intrauterine contraception using different methods of inserting the Lippes D loop. [Anticoncepcion intrauterina con asa de Lippes D. Estudio comparativo con diferentes modalidades de insercion.]
  119. A comparison between the efficacy and side-effects of oral contraception using closely related combined and sequential preparations.
  120. A comparison of the effect of oral contraceptives, pregnancy and sex on iron metabolism.
  121. Comparison of the mechanisms underlying carbohydrate intolerance in subclinical diabetic women during pregnancy and during post-partum oral contraceptive steroid treatment.
  122. Complications due to oral contraceptives. [Les complications dues aux contraceptifs oraux.]
  123. Complications of intra-uterine contraception.
  124. Continuous daily sequential oral steroidal contraception: a preliminary report.
  125. Contraception and psychopathology. [Contraception et psychopathologie.]
  126. Contraception and the Council.
  127. Contraception and the population explosion.
  128. Contraception by an injectable, long-acting oestrogen-progestogen agent.
  129. Contraception in general practice. [Svangerskabsforebyggelse i almen laegepraksis.]
  130. Contraception in Japan.
  131. Contraception, marriage and amorous relations in the Christian west. [Contraception, mariage et relations amoureuses dans l'Occident chretien.]
  132. Contraception.
  133. Contraception. [La contraception.]
  134. Contraception: shape of things to come.
  135. Contraceptive action of the intra-uterine devices in the ferret.
  136. Contraceptive activity of Eugynon. [Antykoncepcy jne dzialanie eugynonu.]
  137. Contraceptive effects on the glycogen content of blood and menstrual discharge.
  138. Contraceptive mechanism of IUDs.
  139. The contraceptive pill in an Indian urban setting.
  140. Contraceptive practice in the United States.
  141. Contraceptive properties of the anti-androgen cyproterone acetate.
  142. Contraceptive steroids and sexual activity.
  143. Contraceptives and cervical carcinoma.
  144. Contraceptives and cervical carcinoma. (Letter)
  145. Contraceptives and cervical carcinoma. (Letter to the editor)
  146. Contraceptives and cervical carcinoma. (Letter to the editor)
  147. Contraceptives and cervical carcinoma. (Letter to the editor)
  148. Contribution to the study of small doses of chlormadinone as a contraceptive. Evaluation of its interference with hormone secretion. [Contribuicao ao estudo de pequenas doses de clormadinona como anticoncepcional. Avaliacao da interferencia nas secrecoes hormonais.]
  149. The control of fertility in a closed community through use of contraceptives. (Abstract only)
  150. Correlation between psychosomatic tendency an discontinuance of family planning.
  151. Cortisol excess and complications of the contraceptive pill.
  152. A cost-effectiveness analysis of selected national family planning programs: A report on phase 2.
  153. Costa Rica (Family planning)
  154. The coupon system in an ongoing family planning program.
  155. Critique of the second report on oral contraceptives (F.D.A., 1 August 1969)
  156. Current research in steroid contraception.
  157. Current status of family planning research and evaluation.
  158. Cycle pattern under treatment with norethisterone enanthate as a depot-contraceptive.
  159. Cyclic endometrial changes in response to monthly injections of an estrogen-progestogen contraceptive drug: a histologic study.
  160. Cytohormonal findings in patients using various forms of contraception.
  161. The Dai study: The Dai-midwife- A local functionary and her role in family planning.
  162. Demography: a necessary and sufficient condition for family planning.
  163. Denmark's assistance in the field of family planning.
  164. Depo-provera (medroxyprogesterone acetate) as a female contraceptive agent.
  165. Depression as a side effect of oral contraceptives.
  166. Depression of physical activity by contraceptive pills.
  167. Desired family size and the efficacy of current family planning programs.
  168. Determining the efficacy rate of contraceptives, using life table techniques.
  169. Development of family planning in the German Democratic Republic.
  170. Development of maternal and child health services in relation to family planning in India.
  171. Diagnosis of cervix uteri carcinoma in a family planning unit. [Pesquisa del carcinoma cervicouterino en una unidad de planificacion familiar.]
  172. Differential effects of education on family planning.
  173. Difficulties in selecting a suitable contraceptive for developing countries.
  174. The diffusion of information about population and family planning in Peru.
  175. Discovering the degree of commitment to family planning in a Calcutta City Project.
  176. Discussion (on contraception by vaccination)
  177. Disturbances in the central vestibular system after oral contraceptives.
  178. Dizziness as related to menstrual cycles and hormonal contraceptives: on electronystagmographic study.
  179. Do oral contraceptives affect diabetes?
  180. Door-to-door canvassing as a means of family planning patient recruitment.
  181. East Pakistan: knowledge and use of contraceptives.
  182. East Pakistan: knowledge and use of contraceptives.
  183. An economic model of family planning and fertility.
  184. Ecuador (Family planning)
  185. Education and family planning.
  186. Education for family planning in a municipal hospital: a 24-month retrospective study of the program in Harlem Hospital Center, New York.
  187. Education for family planning.
  188. Effect of a new low-dosage oral contraceptive pill on blood electrolytes.
  189. Effect of an intrauterine contraceptive device on urea content of uterine fluid.
  190. The effect of an oral contraceptive on tests of thyroid function.
  191. Effect of an oral contraceptive steroid mixture on some aspects of lipid metabolism in the rat.
  192. Effect of contraceptive agents on drug metabolism.
  193. Effect of contraceptive hormone preparations on plasma fibrinolytic activity.
  194. Effect of contraceptive steroids on monoamine oxidase activity.
  195. Effect of different contraceptive treatments on the sodium chloride content of cervical mucus. [Efecto de diversos tratamientos contraceptivos sobre el contenido de cloruro de sodio en el moco cervical.]
  196. The effect of hormonal contraceptives on the vaginal smear pattern.
  197. The effect of oral contraceptives on blood coagulation factors and thromboembolism.
  198. The effect of oral contraceptives on calcium absorption.
  199. Effect of oral contraceptives on carbohydrate metabolism. Study by means of the oral glucose tolerance test. [Efecto de los contraceptivos orales sobre el metabolismo de los carbohidratos. Estudio mediante la curva de tolerancia a la glucosa oral.]
  200. The effect of oral contraceptives on cortisol metabolism.

     

  201. Effect of oral contraceptives on experimental demyelinating disease.
  202. Effect of oral contraceptives on glucose tolerance.
  203. Effect of oral contraceptives on lactation.
  204. Effect of oral contraceptives on serum lipids and lipoproteins.
  205. Effect of oral contraceptives on the blood coagulation in experimental animals.
  206. Effect of ovarian hormones and oral contraceptives on tryptophan metabolism.
  207. Effect of some contraceptive steroids on growth and development of salivary glands and incidence of dental caries in female rats.
  208. The effect of the intrauterine contraceptive device on the mast cell content of the human uterus.
  209. Effectiveness of family planning in Taiwan: a methodology for program evaluation.
  210. The effectiveness of family planning in Taiwan: a proposal for a new evaluation methodology.
  211. Effectiveness of intrauterine contraception: termination levels and correlates.
  212. Effects of a cyclic steroid contraceptive regimen on mammary gland tumor induction in rats.
  213. Effects of a sequential oral contraceptive on endocervical carbohydrate histochemistry.
  214. Effects of different types of oral contraceptives on the protein-bound iodine and the 12-5-I-Triiodothyronine uptake on Sephadex.
  215. Effects of estrogen, progestin and combined estrogen-progestin oral contraceptive preparations on experimental allergic encephalomyelitis.
  216. Effects of gonadal and contraceptive hormones on protein and amino acid metabolism.
  217. Effects of gonadal hormones and contraceptive steroids on glucose and and insulin metabolism.
  218. Effects of gonadal hormones and contraceptive steroids on respiration.
  219. The effects of gonadal hormones and contraceptive steroids on tryptophan metabolism.
  220. Effects of intra-uterine and oral contraceptives on the ultrastructure of the human endometrium.
  221. Effects of oral contraceptives and their components on glucose tolerance in rats.
  222. Effects of oral contraceptives on serum lipid and folate levels. (Abstract only)
  223. Effects of oral contraceptives.
  224. Effects of the oral contraceptives on blood clotting.
  225. The effects on families of putting 'anti-contraception' doctrine into practice.
  226. Egypt. Family planning in Egypt.
  227. Emotional change associated with oral contraceptives in female psychiatric patients.
  228. Emotional factors in the success of contraception.
  229. The Encyclical (Contraception)
  230. Endocervical polypoid hyperplasia in 2 women taking oral contraceptives. [Hyperplasie polypoide endocervicale chez deux femmes prenant un contraceptif oral.]
  231. Endometrial changes related to the presence of an intrauterine contraceptive. Preliminary results. [Modifications de l'endometre liees a la presence d'un contraceptif intra -uterin. Resultats preliminaires.]
  232. Endometrium in the "contraception cycle" under Ovosiston. [Das Endometrium im "Kontrazeptionszyklus" unter Ovosiston.]
  233. Enzymatic and electrophoretic serum examination in long-term therapy with the oral contraceptive. [Enzymatische und elektrophoretische Serumuntersuchungen bei Langzeitther apie mit dem oralen Kontrazeptivum Ovosiston.]
  234. Epilepsy and oral contraception.
  235. Establishing priorities for contraceptive care.
  236. Estimating births averted in a family planning program.
  237. Estimating fertility changes from birth control measures.
  238. Estimating manpower needs for a national family planning program.
  239. Ethiopia. (Family Planning)
  240. Evaluation of a new combination oral contraceptive: lynestrenol-mestranol (lyndiol)
  241. Evaluation of a simple statistical measure for estimating the need for and effectiveness of family planning programs.
  242. An evaluation of depression as a side effect of oral contraceptives.
  243. Evaluation of oral progestogens for contraception in Indian women: a four-year study.
  244. Evaluation of PHS program providing family planning services for American Indians.
  245. An evaluation of the family planning programme of the government of India.
  246. An evaluation of the Intra-uterine contraceptive device. (Abstract only)
  247. Excretion of urinary 17-hydrocorticosteroids and 11-deoxy-17-oxosteroids by women using steroidal contraceptives.
  248. An experience in teaching family planning to medical students.
  249. Experience in the use of the new model of intrauterine contraceptive LVK-66. [Opyt primeneniya novoi modeli vnutrimatochnovo kontratseptiva LVK-66.]
  250. Experience with injectable contraceptives.
  251. Experience with the use of lippes loop inserted early in the puerperium for contraception.
  252. Experiences with Ovosiston for contraception. [Erfahrungen mit Ovosiston Konzeptionsverhutung.]
  253. An experimental family planning program in the Etimesgut Health Region.
  254. Experimental studies on the mode of action of intra-uterine contraceptive device (IUCD)
  255. Eye examinations in patients taking oral contraceptives.
  256. Factors in oral contraception related hypertension.
  257. Factors influencing contraception continuation rates: the oral and the intrauterine methods.
  258. Factors related to knowledge and practice of family planning in East Pakistani villages.
  259. Failure of intrauterine contraceptive device and fungal infection in the fetus.
  260. Family growth and family planning in a rural area in Kenya.
  261. Family planning and family welfare in Asia.
  262. Family planning and public policy: who is misleading whom?
  263. Family planning and teaching in family planning in the medical schools in Taiwan, Republic of China.
  264. Family planning and the reduction of fertility and illegitimacy: a preliminary report on a rural southern program.
  265. Family planning and the reduction of pregnancy loss rates.
  266. Family planning as an essential element in maternal and child health services.
  267. Family planning as perceived by a medical social worker.
  268. Family Planning Association Conference on Health Services and Public Health Act 1968.
  269. Family planning program in Rajasthan.
  270. Family planning programme in Punjab.
  271. Family planning programme in Turkey.
  272. Family planning programs and detection of cervical neoplasia: appropriate partners.
  273. Family planning programs of the Office of Economic Opportunity.
  274. Family planning programs: what they cost and how they work.
  275. Family planning resurvey in Dharwar.
  276. Family planning service: personnel and training.
  277. Family planning services for industrial workers.
  278. Family planning services in the U.S.: a national overview, 1968.
  279. Family planning services--supplies and logistics.
  280. Family planning services.
  281. Family planning via the postpartum approach.
  282. Family planning with norgestrel-ethinyl oestradiol in a private gynecological practice.
  283. Family planning. (Letter to the editor)
  284. Family planning. Two states computerize family planning data. Risk of thromboembolism from use of the pill. Family planning program for American Indians. Measure need-use rates for family planning clinic.
  285. Family planning: a teaching guide for nurses.
  286. Family planning: a factor in the reduction of maternal and child morbidity and mortality.
  287. Family planning: its pitfalls and administration.
  288. Family planning: the Family Planning Association's guide to birth control.
  289. Family planning: theoretical considerations and African models.
  290. Family-planning programs and population control.
  291. Family-planning services in a mental hospital.
  292. Family. Report of the AAMC Institute on Medical Education and Family Planning.
  293. Fasting serum triglyceride and cholesterol levels during oral contraceptive therapy.
  294. Fasting serum triglyceride, cholesterol, and lipoprotein levels during oral-contraceptive therapy.
  295. Fertility and contraception after age forty.
  296. Fertility and family planning in the Etimesgut rural health region.
  297. Fertility, family planning, and the status of women.
  298. Field effectiveness of the oral and the intrauterine methods of contraception; the Baltimore Public Program, 1964-1966.
  299. Fiji (Family planning)
  300. Final report: International Workshop on Communication Aspects of Family Planning Programs, Bangkok, Thailand, 2-4 December 1968.
  301. First experiences with chlormadinone as a contraceptive (Abstract only) [Erste Erfahrungen mit Chlormadinon zur Antikonzeption.]
  302. First experiences with ovosiston in new dosage - a comparative observation of oral contraception with ''old and ''new'' Ovosiston. [Erste Erfahrungen mit Ovosiston in neuer Dosierung - eine vergleichende Betrachtung der oralen Knotrazeption mit Ovosiston ''alt'' uns ''neu.''.]
  303. Five-year plan: Report of Health and Family Planning Sub-Committee, I.M.A., Madras City Branch.
  304. Focus on facets of family planning.
  305. Foreward. (Contraception)
  306. Further observations on the clinical effectivity of new low-dosage oral pills for contraception in Indian women: a four-year study.
  307. Further studies on the effect of oral contraceptives on endocrine function with special reference to luteinising hormone excretion.
  308. Future birth control methods.
  309. Gambia (Family planning)
  310. General practitioners and family planning in Sheffield.
  311. The genetic implications of family planning.
  312. Glucose tolerance and insulin response during daily continuous low-dose oral contraceptive treatment.
  313. The glycogen content of human ectocervical tissue of females receiving steroid contraceptive therapy.
  314. Governmental responsibility for family planning in the United States.
  315. The greater Bombay experiment in family planning.
  316. Growth hormone during treatment with oral contraceptives. [Wachstumhormon bei peroraler Antikonzeptionsbehandlung.]
  317. Guadeloupe (Family planning)
  318. Haiti (Family planning)
  319. Health and demographic priorities for contraception.
  320. Hepatic complications of oral contraceptives: intrahepatic cholestasis of hormonal origin. [Les complications hepatiques des contraceptifs oraux: cholostase intra-hepatique d'origine hormonale.]
  321. Inhibition of sperm capacitation in the cervical canal by norgestrel contraception.
  322. Injectable contraceptive is a single quarterly dosage. [Anovulatorio inyectable en dosis unica trimestral.]
  323. Instruction on irreversible contraception for women, April 21, 1969. [Instruktion uber die irreversible kontrazeption bei der Frau vom 21. April 1969.]
  324. Insulin and glucose determinations after two and three years of use of a combination-type oral contraceptive.
  325. Insulin and glucose studies after 1 year of treatment with a sequential-type oral contraceptive.
  326. Insulin production in overt (maturity-onset) diabetes: absence of hyperinsulinemia despite hyperglycemia induced by contraceptive steroids.
  327. Integration of family planning education in community development.
  328. Intentions to accept family planning: correlates and consequences.
  329. International and domestic organizations involved in family planning activities.
  330. International assistance in family planning.
  331. International family planning, 1966-8: a bibliography.
  332. International Planned Parenthood Federation: a world pioneer.
  333. Interrelationships of oral contraceptives and hypertension.
  334. Intra-uterine contraceptive devices.
  335. Intrauterine contraception in a "double uterus". [Contraception intra-uterine dan un "uterus double".]
  336. Intrauterine contraception. [Die intrauterine Antikonzeption.]
  337. Intrauterine contraception: present status and limitations.
  338. Intrauterine contraceptive devices and their biological effect.
  339. Intrauterine contraceptive devices in women with proven fertility: a 5-year follow-up study.
  340. Intrauterine contraceptive devices: practical considerations in their use.
  341. Intravaginal contraception. [La contraception intravaginale.]
  342. Intravaginal contraception. [La contraception intravaginale.]
  343. Introduction. (Family planning)
  344. Investigation of relation between use of oral contraceptives and thromboembolic disease. a further report.
  345. Involuntary movements in patients taking oral contraceptives.
  346. Iran: family planning in Iran.
  347. Islam and family planning.
  348. The Israel multi-clinic IUD trial: a retrospective exercise in epidemiological reasoning (Presented at the Session on Epidemiology of Fertility and Family Planning of the 97th Annual Meeting of the American Public Health Association, Philadelphia, November 10-14, 1969)
  349. Japan (Family planning)
  350. Korea (South). (Family planning)
  351. The lack of Utopia in birth control.
  352. Late cutaneous porphyria after prolonged treatment with oral contraceptives. [Porphyrie cutanee tardive apres prise prolongee de contraceptifs oraux.]
  353. Legal and administrative aspects of birth control.
  354. The length of the first three menstrual cycles after combined oral contraceptive treatment.
  355. Les dangers de la contraception orale par les steroides oestroprogestatifs. (Dangers of oral contraception by estro-progestogenic steroids.)
  356. The levels of free and conjugated 17-hydroxycorticosteroids (17-OHCS) in the plasma of users of oral contraceptives.
  357. Liver reaction in connection with oral contraceptive steroids.
  358. Living with the pill and other methods of contraception.
  359. Longitudinal studies of the effects of oral contraceptive therapy on plasma glucose, non-esterified fatty acid, insulin, and blood pyruvate levels during oral and intravenous glucose tolerance tests.
  360. Loss of potency in male rhesus monkeys when paired with females receiving contraceptive steroids.
  361. Low dose progestin as a contraceptive. (Abstract only)
  362. Low, lower, lowest? (Oral contraceptives)
  363. Low-dose continuous chlormadinone acetate as an oral contraceptive: a clinical trial.
  364. Luteinizing hormone levels in plasma and urine in women during normal menstrual cycles and in women taking combined contraceptives or chlormadinone acetate.
  365. The "M," a new intrauterine contraceptive device.
  366. Macular manifestations associated with usage of contraceptive pills. [Manifestations maculaires au cours de l'usage de la pilule.]
  367. Major federal resources for family planning programs and services: a summary.
  368. Making and marketing birth control products.
  369. Malabsorption of folate polyglutamates associated with oral contraceptive therapy.
  370. Malabsorption of polyglutamic folic acid secondary to oral contraceptives.
  371. Malaysia (West) (Family planning)
  372. Malignant hypertension associated with oral contraceptives.
  373. The man's stake in birth control.
  374. Mandate and summary of current activities: Health aspects of human reproduction, of family planning and of population dynamics, 1968-1969.
  375. A manual of clinical contraception.
  376. Manual of family planning records and returns.
  377. A mathematical model study of contraceptive efficiency and unplanned pregnancies.
  378. Mauritius. (Family planning)
  379. The means of measurement of the impact of a family planning programme.
  380. Measurement of need and utilization rates for a public family planning program.
  381. Measures, policies and programmes affecting fertility, with particular reference to national family planning programmes: provisional report of the Secretary-General.
  382. The mechanism of action of oral contraceptives.
  383. Medical and psychological aspects of the temperature method of contraception. [Aspetti medico-psicologici della regolazione delle nascite mediante temperatura basale.]
  384. Medical and social hazards of birth control. [Dano medico-social de contralor dirigido de la natalidad.]
  385. Medical education and family planning in Mexico.
  386. Medical education and family planning--I. Departmental suggestions.
  387. Medical education and family planning-II. Implementation of administrative recommendations for the Third Conference of Deans and Principals.
  388. The medical history of contraception.
  389. Medical students and community-based family planning programs.
  390. Medicolegal aspects of contraception.
  391. Medroxyprogesterone acetate - prolonged-action progestogen. Report on its use as a contraceptive. [Acetato de medroxi-progesterona - un progestageno de efecto prolongado. Comunicacion sobre su empleo como anticincepcional.]
  392. Meeting the need for family planning in Kenya: a series of informal proposals.
  393. Menstrual abnormalities following the use of oral contraceptives.
  394. Mental and sexual adjustment before and after six months' use of an oral contraceptive.
  395. Metabolic effects of oral contraceptives.

     

  396. Metabolic effects of oral contraceptives.
  397. Metabolism of (U-carbon-14) glucose in the rat uterus in the presence of an intra-uterine contraceptive device.
  398. Metallic copper as an intrauterine contraceptive adjunct to the "T" device.
  399. Methods and results of surveys for evaluation of family planning.
  400. Methods of family planning. Book 3: The oral pill.
  401. Methods of family planning: Book 2. The Loop.
  402. Mini pills as oral contraceptives. (Abstract only)
  403. Minor hepatic involvement during use of estrogen-progestogen contraceptives. [Les retentissements hepatiques mineurs lors de l'utilisation des oestroprogestatifs anticonceptionelles.]
  404. Minority Papal Commission Report (Contraception)
  405. The mode of action of an intrauterine contraceptive device.
  406. Mode of action of intra-uterine contraceptive devices in women.
  407. Modern methods of birth control: an evaluation.
  408. Modern methods of contraception: an assessment of effectiveness, acceptability, and safety.
  409. Modern methods of intrauterine contraception (author's transl) [Nowoczesne metody antykoncepcji wewnatrzmacicznej.]
  410. Modernization and attitude toward family size and family planning: analysis of some data from India.
  411. Modernization and birth control before the organized program.
  412. Modified sequential oral contraception employing mestranol with chlormadinone.
  413. Monthly bleeding with the use of sequential type oral contraceptives. [Manedly blodtap ved bruk av p-pille av sekvenstype.]
  414. Montserrat (Family planning)
  415. Morocco: training and utilization of family planning field workers.
  416. The morphologic effects of oral contraceptive agents on the cervix.
  417. Motivational correlates of family planning among government employees.
  418. Natural history of contraceptive practice among postpartum loop acceptors.
  419. The need for educational innovations and research in family planning programmes.
  420. Nepal: national development, population, and family planning.
  421. Netherlands Antilles (Curacao) (Family Planning)
  422. New approaches in hormonal contraceptives and possible future.
  423. A new contraceptive device with reduced expulsion rate.
  424. New frontiers in contraceptive research.
  425. A New Guinea cinnamon used as a contraceptive.
  426. A new low-dose combination oral contraceptive.
  427. A new postcoital oral contraceptive.
  428. Nigeria. (Family planning)
  429. Nigeria: cultural barriers to family planning among the Yorubas.
  430. Non-family planning methods of population control.
  431. Nonuse of family planning by poor whites.
  432. Norethisterone enanthate. Studies during the use of a depot parenteral contraceptive. [Norethisterononanthat. Untersuchungen wahrend der Anwendung eines langwirkenden parenteralen Kontrazeptivum.]
  433. Northisterone enanthate as a prolonged-action contraceptive: observations on 450 cases. [Enantato de nor-etisterona como anticonceptivo de deposito: observaciones de 450 casos.]
  434. Nursing and midwifery in family planning.
  435. Observations and recommendations on mass communications and family planning.
  436. Observations on a motivational study of birth control. [Considerazioni in margine ad una indagine motivazionale sul controllo delle nascite.]
  437. Oestrogen content of oral contraceptives.
  438. On a survey of vascular complications of oral contraceptives. [A propos d'une enquete sur les accidents vasculaires des contraceptifs oraux.]
  439. On the beginning of contraception in France or the two Malthusianisms. [Sur les debuts de la contraception en France ou les deux malthusianismes.]
  440. Oral contraception and depression.
  441. Oral contraception and depression. [Oral antikonsepsjon og depresjon.]
  442. Oral contraception and gynecological therapy. [Orale Kontrazeption und gynakologische Therapie.]
  443. Oral contraception started early in the puerperium: a clinical study.
  444. Oral contraception with a new combination of lynestrenol (1 mg) and mestranol (0.1 mg)
  445. Oral contraception, coital frequency and the time required to conceive.
  446. Oral contraception.
  447. Oral contraceptive and folate deficiency.
  448. An oral contraceptive as an etiologic factor in producing hyperplastic gingivitis and a neoplasm of the pregnancy tumor type.
  449. Oral contraceptive drugs: some observations on their effect on menstrual loss and hematological indices.
  450. Oral contraceptive hypertrophic gingivitis.
  451. Oral contraceptive medications and headache.
  452. Oral contraceptive medications and vulvovaginal candidiasis.
  453. Oral contraceptive pilot projects, their initiation and their present status.
  454. The oral contraceptive.
  455. Oral contraceptives and blood coagulation.
  456. Oral contraceptives and blood pressure.
  457. Oral contraceptives and blood pressure.
  458. Oral contraceptives and blood-iron.
  459. Oral contraceptives and blood-iron. (Letter to the editor.)
  460. Oral contraceptives and blood-pressure.
  461. Oral contraceptives and carcinom-in-situ.
  462. Oral contraceptives and cell division) [Les contraceptifs oraux et la replication cellulaire.]
  463. Oral contraceptives and cerebral arterial thrombosis.
  464. Oral contraceptives and cerebrovascular complications.
  465. Oral contraceptives and cervical atypia: a plea for objective appraisal.
  466. Oral contraceptives and cervical cancer: a preliminary report of an experimental study.
  467. Oral contraceptives and depression.
  468. Oral contraceptives and depression.
  469. Oral contraceptives and depression.
  470. Oral contraceptives and depression.
  471. Oral contraceptives and excess mortality from venous and pulmonary thromboembolism in the United States.
  472. Oral contraceptives and eye changes.
  473. Oral contraceptives and folate metabolism. (Letter to the editor)
  474. Oral contraceptives and glucose tolerance.
  475. Oral Contraceptives and glucose tolerance.
  476. Oral contraceptives and glucose tolerance. [Contraceptifs oraux et tolerance glucidique.]
  477. Oral contraceptives and heart infarct. [Oral antikonsepsjon og hjerteinfarkt.]
  478. Oral contraceptives and high blood pressure: changes in plasma renin, renin substrate and aldosterone excretion.
  479. Oral contraceptives and hypertension.
  480. Oral contraceptives and immune responses.
  481. Oral contraceptives and jaundice: Swedish experience.
  482. Oral contraceptives and malignant hypertension.
  483. Oral contraceptives and mortality trends from thromboembolism in the United States.
  484. Oral contraceptives and neuro-ophthalmologic disorders.
  485. Oral contraceptives and prophylaxis of thromboembolism.
  486. Oral contraceptives and prophylaxis of thromboembolism.
  487. Oral contraceptives and psychological symptoms.
  488. Oral contraceptives and relative risk of death from venous and pulmonary thromboembolism in the United States.
  489. Oral contraceptives and thromboembolic disease.
  490. Oral contraceptives and thromboembolic disease.
  491. Oral contraceptives and thromboembolic disease.
  492. Oral contraceptives and thromboembolic disease.
  493. Oral contraceptives and thromboembolism.
  494. Oral contraceptives and thromboembolism.
  495. Oral contraceptives and thromboembolism.
  496. Oral contraceptives and thromboembolism. [Peroralni kontraceptivi i tromboembolizam.]
  497. Oral contraceptives and urokinase activity.
  498. Oral contraceptives contain oestrogens. (Dunlop committee statement)
  499. Oral contraceptives containing oestrogens [letter]
  500. Oral contraceptives containing oestrogens. A statement by the Committee on Safety of Drugs.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.